Annual screening for tuberculosis in patients on TNF-alfa antagonists - 17/08/15
Doi : 10.1016/j.jaad.2015.04.071
Sean D. Doherty, MD a, Mark G. Lebwohl, MD b, Abby S. Van Voorhees, MD c, Neil J. Korman, MD, PhD d, Sylvia Hsu, MD e, ⁎ 
a Permanente Medical Group, Kaiser Permanente, Roseville, CA
b Icahn School of Medicine at Mount Sinai, New York, NY
c University of Pennsylvania School of Medicine, Philadelphia, PA
d Case Western Reserve University School of Medicine, Cleveland, OH
e Baylor College of Medicine, Houston, TX
∗Correspondence to: Sylvia Hsu, MD, Baylor College of Medicine, 1977 Butler Blvd, Suite E6.200, Houston, TX 77030
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Lebwohl is an employee of the Mount Sinai Medical Center which receives research funds from AbGenomics, AbbVie, Amgen, Anacor, Aqua, Can-Fite Biopharma, Celgene, Clinuvel, Coronado Biosciences, Ferndale, Lilly, Janssen Biotech, LEO-pharma, Merz, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Valeant. Dr Van Voorhees served on the advisory board and was an investigator, speaker, and consultant for Amgen receiving grants and honoraria; was investigator, advisory board member, and speaker for Abbvie receiving honoraria; was an advisory board member and speaker for Janssen receiving honoraria. She sits on the advisory board for Celgene, LEO Pharmaceuticals, Pfizer, and Novartis receiving honoraria. She also receives other monies from Merck (ex-spouse pension). Dr Korman has served on the advisory board and was investigator for Celgene, Eli Lilly, and Pfizer for which he received honoraria and grants. He has served on the advisory board for Novartis where he received honoraria. For Janssen he has served as advisor, investigator, and speaker receiving grants, funding, and honoraria. He has served Abbott and Amgen as investigator and speaker, and as a member of the advisory board for Amgen receiving grants and honoraria. Genentech and Astellas host him as a speaker and advisor. He has served as an investigator for Genentech and a consultant for Astellas receiving grants and honoraria and speaker for Genentech and Astellas receiving grants and honoraria. Dr Hsu served on the advisory board for Abbott, Abbvie, Amgen, Biogen, Centocor, Dermik, Eli Lilly, Genentech, Janssen, Medicis, and Novartis for which she received honoraria. She has been an investigator for Amgen, Centocor, Galderma, Novartis, 3M Pharmaceuticals, and PharmaDerm for which her department received funding. Dr Doherty has no conflicts of interest to declare. |
© 2015
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 73 - N° 3
P. e123 - septembre 2015 Retour au numéro
Article précédent
- Comment on “Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors”
- Kathleen E. Gilbert, Iviensan F. Manalo, Jashin J. Wu
- Reply to: “Comment on ‘Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors’”
- Karynne O. Duncan, Kevin L. Winthrop
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?